Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy

Yuji Kashiwakura, Yuto Nakajima, Kio Horinaka, Tiago J.S. Lopes, Yuma Furuta, Yuki Yamaguchi, Nemekhbayar Baatartsogt, Morisada Hayakawa, Yuko Katakai, Susumu Uchiyama, Osamu Nureki, Keiji Nogami, Tsukasa Ohmori

Blood blood.2025028481.

https://doi.org/10.1182/blood.2025028481

Published: 2025

Includes: Supplemental data

Journal Articles

Tissue factor pathway inhibitor-reduced and antithrombin-reduced hemophilia state exhibit different coagulation responses to bypassing agents

Shigeharu Oh, Yuto Nakajima, Eisuke Takami, Hirotoshi Nakano, Keiji Nogami

Blood (2025) 146 (Supplement 1): 3050.

https://doi.org/10.1182/blood-2025-3050

Published: 2025

Journal Articles

Clinical outcomes up to 4 years of once-weekly efanesoctocog alfa prophylaxis in previously treated adults, adolescents, and children with severe hemophilia A: Interim analysis of the Phase 3 XTEND-ed long-term extension study

Sophie Susen, Anthony Chan, Pratima Chowdary, Stephanie P'ng, Manuela Albisetti, Keiji Nogami, Karin Fijnvandraat, Jennifer Dumont, Elena Santagostino, Sriya Gunawardena, Mahnouch Georget, Lynn Malec

Blood (2025) 146 (Supplement 1): 539.

https://doi.org/10.1182/blood-2025-539

Published: 2025

Journal Articles

AKATSUKI third interim analysis: Safety of emicizumab during and after immune tolerance induction implementation

Keiji Nogami, Nobuaki Suzuki, Chiai Nagae, Azusa Nagao, Masahiko Ando, Yachiyo Kuwatsuka, Akiko Ioka, Yoichi Murakami, Tomomi Shimura, Tadashi Matsushita

Blood (2025) 146 (Supplement 1): 303.

https://doi.org/10.1182/blood-2025-303

Published: 2025

Journal Articles

Ex vivo evaluation of the procoagulant effect of NXT007 prophylaxis in people with Hemophilia A without factor VIII inhibitors: Phase I/II study (NXTAGE)

Keiji Nogami, Takeshi Miyake, Megumi Yamanaka, Takuya Miwa, Chun-An Chen, Ryota Kobayashi, Midori Shima

Blood (2025) 146 (Supplement 1): 3061.

https://doi.org/10.1182/blood-2025-3061

Published: 2025

Journal Articles

Assessment of coagulation potential of concomitant factor VIII administration in patients with haemophilia a receiving emicizumab prophylaxis (CAGUYAMA Study): A multicenter, open-label, non-randomized clinical trial

Blood (2025) 146 (Supplement 1): 4847.

https://doi.org/10.1182/blood-2025-4847

Published: 2025

Journal Articles

Human hepatocyte engraftment in F8KO TK-NOG mice: Creating a novel Hemophilia A mouse model with functional human coagulation cascade

Naoki Matsumoto, Asuka Sakata, Kohei Tatsumi, Suguru Harada, Ryohei Kawasaki, Motohito Goto, Tetsuhiro Soeda, Midori Shima, Keiji Nogami

Blood (2025) 146 (Supplement 1): 1291.

https://doi.org/10.1182/blood-2025-1291

Published: 2025

Journal Articles

Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors: 96-Week Interim Analysis of the AKATSUKI Study

Azusa Nagao, Keiji Nogami, Nobuaki Suzuki, Chiai Nagae, Masahiko Ando, Yachiyo Kuwatsuka, Daisuke Nosaka, Yui Kyogoku, Tomomi Shimura, Tadashi Matsushita

Blood (2024) 144 (Supplement 1): 2588.

https://doi.org/10.1182/blood-2024-193535

Published: 2024

Journal Articles

Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study

Allison P. Wheeler, Aby Abraham, Chris Barnes, Renée Brown Frandsen, Kingsley Hampton, Francisco José López Jaime, Camila Martins Mazini Tavares, Keiji Nogami, Jerzy Windyga, Giancarlo Castaman

Blood (2024) 144 (Supplement 1): 2585.

https://doi.org/10.1182/blood-2024-209752

Published: 2024

Journal Articles

Clinical Outcomes over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study

Robert Klamroth, Stephanie P'ng, Sophie Susen, Davide Matino, Pratima Chowdary, Angela C Weyand, Toshko Lissitchkov, Young-Shil Park, María Teresa Alvarez-Román, Liqi Feng, Helena Palmborg, Jennifer Dumont, Elena Santagostino, Lara Mamikonian, Keiji Nogami

Blood (2024) 144 (Supplement 1): 717.

https://doi.org/10.1182/blood-2024-204533

Published: 2024

Journal Articles

TSUBASA Study: A Prospective Study Evaluating the Association between Physical Activity and Bleeding Events, Quality of Daily Life, and Safety in People with Hemophilia A without FVIII Inhibitors

Keiji Nogami, Teruhisa Fujii, Akihiro Sawada, Azusa Nagao, Chiai Nagae, Masanori Nojima, Nobuaki Suzuki, Mika Kawano, Tomomi Shimura, Yoshimasa Sugao, Kagehiro Amano

Blood (2024) 144 (Supplement 1): 1211.

https://doi.org/10.1182/blood-2024-193537

Published: 2024

Journal Articles

Impact of Anticoagulant Function By the Addition of Heparinoid in Vitro in the Plasmas from Patients with Hemophilia and Von Willebrand Disease

Masahiro Takeyama, Tomoya Miyatake, Shoko Furukawa, Kenichi Ogiwara, Keiji Nogami

Blood (2023) 142 (Supplement 1): 5469.

https://doi.org/10.1182/blood-2023-174793

Published: 2023

Journal Articles

The Effect of Concizumab Prophylaxis on Target Joints, Resolution and Joint Bleeds in Patients With Hemophilia A or B With or Without Inhibitors in Phase 3 Clinical Trials

Giancarlo Castaman, Aby Abraham, Pantep Angchaisuksiri, Laura Villarreal Martinez, Keiji Nogami, Jameela Sathar, Chunduo Shen, Jay Jay Thaung Zaw, Guy Young

Blood (2023) 142 (Supplement 1): 284.

https://doi.org/10.1182/blood-2023-180790

Published: 2023

Journal Articles

Three-Year Interim Analysis Results of the AOZORA Study to Evaluate the Long-Term Safety and Joint Health in Children with Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab

Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Chiai Nagae, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Hiroki Oki, Keisuke Iwasaki, Keiji Nogami

Blood (2023) 142 (Supplement 1): 3991.

https://doi.org/10.1182/blood-2023-173073

Published: 2023

Journal Articles

Research and Evaluation of the Diagnostic Precision of an Artificial Intelligence Algorithm Using Ultrasound Images for Early Diagnosis of Arthropathy in People with Hemophilia

Azusa Nagao, Yusuke Inagaki, Keiji Nogami, Naoya Yamasaki, Fuminori Iwasaki, Yang Liu, Yoichi Murakami, Takahiro Ito, Hideyuki Takedani

Blood (2023) 142 (Supplement 1): 3645.

https://doi.org/10.1182/blood-2023-174054

Published: 2023

Journal Articles

AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors

Tadashi Matsushita, Nobuaki Suzuki, Chiai Nagae, Azusa Nagao, Masahiko Ando, Yachiyo Kuwatsuka, Daisuke Nosaka, Yui Kyogoku, Tomomi Shimura, Keiji Nogami

Blood (2023) 142 (Supplement 1): 2625.

https://doi.org/10.1182/blood-2023-173071

Published: 2023

Journal Articles

Contribution of the Residues 488-490 on the Factor (F)VIII A2 Domain and the Residue 2239 on the FVIII C2 Domain for the Interaction between FVIII and Protein S

Shoko Furukawa, Masahiro Takeyama, Keiji Nogami

Blood (2023) 142 (Supplement 1): 2603.

https://doi.org/10.1182/blood-2023-174626

Published: 2023

Journal Articles

ORIHIME II Study: Background, Treatment Status, and Outcomes of Patients with Acquired Hemophilia A with Low Activities of Daily Living Scores or Undergoing Rehabilitation - a Japanese Health Claims Database Analysis

Yoshiyuki Ogawa, Kagehiro Amano, Akiko Ioka, Daisuke Nosaka, Yoichi Murakami, Hiroki Adachi, Keiji Nogami

Blood (2022) 140 (Supplement 1): 5627–5628.

https://doi.org/10.1182/blood-2022-157170

Published: 2022

Journal Articles

Escaping Ability of Human-Porcine Hybrid Factor VIII from Anti-Factor VIII Inhibitors with an A2 or C2 Epitope

Kuniyoshi Mizumachi, Yuto Nakajima, Naruto Shimonishi, Shoko Furukawa, Kenichi Ogiwara, Masahiro Takeyama, Midori Shima, Keiji Nogami

Blood (2022) 140 (Supplement 1): 8430–8431.

https://doi.org/10.1182/blood-2022-165714

Published: 2022

Journal Articles

AOZORA Study: Interim Analysis of Joint Health in Children with Hemophilia A, without FVIII Inhibitors, 3 Years after Initiating Emicizumab

Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Keisuke Iwasaki, Keiji Nogami

Blood (2022) 140 (Supplement 1): 2742–2744.

https://doi.org/10.1182/blood-2022-157249

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy

Tissue factor pathway inhibitor-reduced and antithrombin-reduced hemophilia state exhibit different coagulation responses to bypassing agents

Clinical outcomes up to 4 years of once-weekly efanesoctocog alfa prophylaxis in previously treated adults, adolescents, and children with severe hemophilia A: Interim analysis of the Phase 3 XTEND-ed long-term extension study

AKATSUKI third interim analysis: Safety of emicizumab during and after immune tolerance induction implementation

Ex vivo evaluation of the procoagulant effect of NXT007 prophylaxis in people with Hemophilia A without factor VIII inhibitors: Phase I/II study (NXTAGE)

Assessment of coagulation potential of concomitant factor VIII administration in patients with haemophilia a receiving emicizumab prophylaxis (CAGUYAMA Study): A multicenter, open-label, non-randomized clinical trial

Human hepatocyte engraftment in F8KO TK-NOG mice: Creating a novel Hemophilia A mouse model with functional human coagulation cascade

Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors: 96-Week Interim Analysis of the AKATSUKI Study

Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study

Clinical Outcomes over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study

TSUBASA Study: A Prospective Study Evaluating the Association between Physical Activity and Bleeding Events, Quality of Daily Life, and Safety in People with Hemophilia A without FVIII Inhibitors

Impact of Anticoagulant Function By the Addition of Heparinoid in Vitro in the Plasmas from Patients with Hemophilia and Von Willebrand Disease

The Effect of Concizumab Prophylaxis on Target Joints, Resolution and Joint Bleeds in Patients With Hemophilia A or B With or Without Inhibitors in Phase 3 Clinical Trials

Three-Year Interim Analysis Results of the AOZORA Study to Evaluate the Long-Term Safety and Joint Health in Children with Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab

Research and Evaluation of the Diagnostic Precision of an Artificial Intelligence Algorithm Using Ultrasound Images for Early Diagnosis of Arthropathy in People with Hemophilia

AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors

Contribution of the Residues 488-490 on the Factor (F)VIII A2 Domain and the Residue 2239 on the FVIII C2 Domain for the Interaction between FVIII and Protein S

ORIHIME II Study: Background, Treatment Status, and Outcomes of Patients with Acquired Hemophilia A with Low Activities of Daily Living Scores or Undergoing Rehabilitation - a Japanese Health Claims Database Analysis

Escaping Ability of Human-Porcine Hybrid Factor VIII from Anti-Factor VIII Inhibitors with an A2 or C2 Epitope

AOZORA Study: Interim Analysis of Joint Health in Children with Hemophilia A, without FVIII Inhibitors, 3 Years after Initiating Emicizumab

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only